Medeon Biodesign Statistics

Total Valuation

Medeon Biodesign has a market cap or net worth of TWD 3.69 billion. The enterprise value is 2.51 billion.

Market Cap	3.69B
Enterprise Value	2.51B

Important Dates

The next estimated earnings date is Thursday, March 6, 2025.

Earnings Date	Mar 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Medeon Biodesign has 92.14 million shares outstanding. The number of shares has increased by 0.09% in one year.

Current Share Class	n/a
Shares Outstanding	92.14M
Shares Change (YoY)	+0.09%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	12.30%
Owned by Institutions (%)	3.49%
Float	46.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.60
PB Ratio	2.14
P/TBV Ratio	2.37
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.14
EV / Sales	9.28
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.70

Financial Position

The company has a current ratio of 7.87, with a Debt / Equity ratio of 0.10.

Current Ratio	7.87
Quick Ratio	7.56
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	-0.19
Interest Coverage	-148.37

Financial Efficiency

Return on equity (ROE) is -39.77% and return on invested capital (ROIC) is -22.93%.

Return on Equity (ROE)	-39.77%
Return on Assets (ROA)	-21.46%
Return on Capital (ROIC)	-22.93%
Revenue Per Employee	6.95M
Profits Per Employee	-20.55M
Employee Count	39
Asset Turnover	0.11
Inventory Turnover	11.02

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.62% in the last 52 weeks. The beta is 0.71, so Medeon Biodesign's price volatility has been lower than the market average.

Beta (5Y)	0.71
52-Week Price Change	-14.62%
50-Day Moving Average	44.28
200-Day Moving Average	44.35
Relative Strength Index (RSI)	33.75
Average Volume (20 Days)	49,016

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Medeon Biodesign had revenue of TWD 270.93 million and -801.29 million in losses. Loss per share was -8.70.

Revenue	270.93M
Gross Profit	72.84M
Operating Income	-869.86M
Pretax Income	-857.42M
Net Income	-801.29M
EBITDA	-826.58M
EBIT	-869.86M
Loss Per Share	-8.70

Full Income Statement

Balance Sheet

The company has 1.38 billion in cash and 179.21 million in debt, giving a net cash position of 1.20 billion or 13.06 per share.

Cash & Cash Equivalents	1.38B
Total Debt	179.21M
Net Cash	1.20B
Net Cash Per Share	13.06
Equity (Book Value)	1.75B
Book Value Per Share	18.66
Working Capital	1.33B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -865.51 million and capital expenditures -65.62 million, giving a free cash flow of -931.13 million.

Operating Cash Flow	-865.51M
Capital Expenditures	-65.62M
Free Cash Flow	-931.13M
FCF Per Share	-10.11

Full Cash Flow Statement

Margins

Gross margin is 26.88%, with operating and profit margins of -321.06% and -295.75%.

Gross Margin	26.88%
Operating Margin	-321.06%
Pretax Margin	-316.47%
Profit Margin	-295.75%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Medeon Biodesign does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.09%
Shareholder Yield	-0.09%
Earnings Yield	-21.75%
FCF Yield	-25.26%

Dividend Details

Stock Splits

The last stock split was on August 23, 2023. It was a forward split with a ratio of 1.049992864.

Last Split Date	Aug 23, 2023
Split Type	Forward
Split Ratio	1.049992864

Scores

Medeon Biodesign has an Altman Z-Score of 6.65.

Altman Z-Score	6.65
Piotroski F-Score	n/a